Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,015 | $829 | $660 | $443 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Cost of Goods Sold | $159 | $192 | $139 | $81 |
| Gross Profit | $856 | $637 | $521 | $362 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| R&D Expenses | $79 | $76 | $67 | $36 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $154 | $149 | $144 | $50 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $71 | $74 | $43 | $0 |
| Operating Expenses | $304 | $299 | $253 | $86 |
| Operating Income | $551 | $338 | $268 | $276 |
| % Margin | 54.3% | 40.7% | 40.5% | 62.2% |
| Other Income/Exp. Net | $6 | $11 | -$19 | -$27 |
| Pre-Tax Income | $557 | $348 | $249 | $249 |
| Tax Expense | $113 | $67 | $47 | -$154 |
| Net Income | $444 | $282 | $202 | $403 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS | 3.5 | 2.13 | 1.48 | 2.86 |
| % Growth | 64.3% | 43.9% | -48.3% | – |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| Weighted Avg Shares Out | 127 | 132 | 137 | 141 |
| Weighted Avg Shares Out Dil | 129 | 134 | 141 | 147 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18 | $19 | $17 | $8 |
| Depreciation & Amortization | $81 | $85 | $50 | $3 |
| EBITDA | $657 | $452 | $316 | $259 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |